| Autor: |
Bohlen, Krista N., Kittelsrud, Julie M., Nelson, Morgan E., Weisser, Lisa K., Matthiesen, Neil J., Fieldsend, Julie A., Buschette, Nicholas B., Cooper, Leslie L., Davies, Gareth E., Ehli, Erik A. |
| Zdroj: |
The Pharmacogenomics Journal; January 2023, Vol. 23 Issue: 1 p21-27, 7p |
| Abstrakt: |
This study evaluated the timing, use, and clinical outcomes of the GeneFolio® Pharmacogenomic Panel in a healthcare setting with patients managed by primary care providers or by psychiatrists. Participants were randomized to receive a pharmacogenetics report at four weeks or 12 weeks. After DNA collection and genetic analysis, pharmacists produced a recommendation report which was given to providers at the randomization week. The four-week group decreased depression severity (PHQ-9 and BDI) faster than the 12-week group (p= 0.0196), and psychiatrists’ patients decreased their depression severity faster than primary care patients (PHQ-9 p= 0.0005, BDI p= 0.0218). Mean mental quality of life increased over time (p< 0.0001), but it increased slower for patients taking drugs in the Significant drug-drug-gene interaction category (p= 0.0012). Mental quality of life, depression severity, and clinical outcomes were improved by GeneFolio® pharmacogenomic testing regardless of provider type, with earlier testing improving outcomes sooner. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full text from SpringerLink